Luke Halpern is an assistant editor with Pharmacy Times. Luke wrote for Pharmacy Times in the summer of 2023, and assumed a full-time role in June 2024. His work has been featured in Pharmacy Times and the American Journal of Managed Care. He graduated from the University of Massachusetts, Amherst in May 2024.
PCSK9 Inhibitors Found Safe, Effective in Solid Organ Transplant Recipients
September 16th 2025A series of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were found to be tolerable and effective at reducing low-density lipoprotein cholesterol in solid organ transplant recipients.
Read More
Novel PCSK9 Inhibitor Recaticimab Lowers LDL-C in Adult Heterozygous Familial Hypercholesterolemia
September 12th 2025Recaticimab significantly lowered low-density lipoprotein cholesterol (LDL-C) levels, showing promise in becoming a future proprotein convertase subtilisin/kexin type 9 (PCSK9) option for cholesterol reduction.
Read More
Novel Conditioning Strategies Emerge in Gene Therapy, Leaving Busulfan—and Toxicities—Behind
September 12th 2025Speakers at an ASTCT Gene Therapy Summit highlighted novel conditioning approaches without the use of busulfan, which can cause toxic effects in patients with hematologic malignancies.
Read More
PCV21 Shows Favorable Immunogenicity in Infants, Toddlers Receiving Pediatric Vaccines
September 10th 2025The 21-valent pneumococcal conjugate vaccine (PCV21) elicited favorable immunogenicity and safety in infants and toddlers who were coadministered common pediatric vaccines, such as the measles-mumps-rubella vaccine.
Read More
Inclisiran With LLT Reduces LDL-C in Hypercholesterolemia Without Inducing Muscle Pain
September 9th 2025In combination with lipid-lowering therapy, inclisiran allowed patients with hypercholesterolemia to reach their low-density lipoprotein cholesterol (LDL-C) goals without associated muscle-related adverse events.
Read More
Expert: Zongertinib Offers Well-Tolerated, Convenient Oral Option for HER2-Mutant NSCLC
September 8th 2025Joshua K. Sabari, MD, explains zongertinib’s (Hernexeos) favorable safety profile and quality-of-life benefits over intravenous antibody-drug conjugates in patients with HER2-mutated non-small cell lung cancer (NSCLC).
Read More
Full Phase 3 Results Indicate Reduced Blood Pressure With Baxdrostat in Hypertension
September 8th 2025The trial results, which showed baxdrostat significantly reduced mean seated systolic blood pressure in uncontrolled hypertension, were presented at the 2025 European Society of Cardiology Congress.
Read More
Insights: NCCN Adds Zongertinib as Preferred Therapy for HER2-Mutant NSCLC
September 6th 2025Joshua K. Sabari, MD, discusses how zongertinib’s inclusion in the National Comprehensive Care Network (NCCN) guidelines represents a game-changing second-line treatment for HER2-mutant non-small cell lung cancer (NSCLC).
Read More
AMCP CEO Raises Concerns Over ACIP Changes, Stresses Pharmacists’ Expanding Public Health Role
September 5th 2025Susan Cantrell, RPh, MHL, CAE, CEO of the Academy of Managed Care Pharmacy (AMCP), warns that politicizing the Advisory Committee on Immunization Practices (ACIP) could undermine vaccine trust.
Read More
Expert: APhA Empowers Pharmacists to Tackle Vaccine Hesitancy, Pharmacy Deserts
September 4th 2025Allison Hill, PharmD, RPh, highlights the need for pharmacists to leverage resources, collaborate with other providers, advocate on social media, and support rural communities with limited access to care.
Read More
Expert: ECAPS Act Could Sustain Pharmacists’ Public Health Role Postpandemic
September 2nd 2025Susan Cantrell, RPh, MHL, CAE, highlights the Equitable Community Access to Pharmacy Services (ECAPS) Act as the top federal priority to preserve pharmacists’ authority in testing, treatment, and immunization services.
Read More
AMCP CEO: Pharmacists’ Communication, Trust-Building Key to Addressing Vaccine Hesitancy
August 31st 2025Susan Cantrell, RPh, MHL, CAE, CEO of the Academy of Managed Care Pharmacy, stresses the importance of listening, empathy, and science-based communication in pharmacists’ efforts to guide patients through vaccine decisions.
Read More